Clinical Trial Update: Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial of bendamustine plus obinutuzumab induction with obinutuzumab maintenance in untreated mantle cell lymphoma; the study is terminated, with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Gazyva (Obinutuzumab)
• Treanda (Bendamustine)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Mantle Cell Lymphoma, Non-hodgkin Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2024-10-24